The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...] …
Year: 2024
Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...] …
Exclusive
Former Senior Trump Official Talks Drug Pricing Reform, Says 340B Program Is ‘Out of Control’
A key official in the former Trump administration raised serious concerns with the 340B program during the keynote address at [...] …
An influential drug industry expert said that he expects Johnson & Johnson (J&J) to sue the government over its refusal [...] …
SPONSORED CONTENT
The 340B Drug Pricing Program offers significant savings to eligible healthcare organizations, enabling them to stretch scarce resources further and provide better services to their communities. However, ensuring your program captures the maximum potential savings and operates optimally requires close monitoring of
…
A political action committee (PAC) that funded efforts opposing state 340B contract pharmacy access bills through misleading claims linking the [...] …
An influential California newspaper recently urged against a November ballot measure, which would require certain healthcare providers in the state [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...] …
The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...] …